Clinical trials: Clopidogrel, completed
Acute Ischemic Stroke
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke
The hypothesis of this study is that "the poor metabolizer or intermediate metabolizer of the cytochrome P450 2C19 genotype in patients with acute ischemic stroke is associated with increased risk of composite cardiovascular…
- Trial name
- NCT04072705
- Testing
- General principles of care and judgement of researcher
- Where
- 37 sites in South Korea
- Volunteers
- 2,927 people
- Sponsor
- Gangnam Severance Hospital
Acute Coronary Syndrome, Atrial Fibrillation
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is challenging.
- Trial name
- EPIDAURUS (NCT04981041)
- Testing
- Prasugrel or Ticagrelor, Clopidogrel
- Where
- 37 sites in Austria, Germany
- Volunteers
- 602 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Healthy
Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
Primary Objective: Investigate the possible role of the CYP2C19 genotype in Adenosine diphosphate (ADP)-induced platelet aggregation after administration of a standard dose regimen of clopidogrel (300 mg loading dose followed by…
- Trial name
- NCT01123824
- Testing
- CLOPIDOGREL
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Myocardial Infarction
Ticagrelor for PCI Post Thrombolysis
Ticagrelor is a first line therapy along with aspirin for patients undergoing primary PCI for STEMI. However, many patients are still treated with fibrinolytic therapy and the safety and efficacy of Ticagrelor has not been…
- Trial name
- SETFAST (NCT01930591)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 5 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Unity Health Toronto
Stroke, Ischemic Attack, Transient
Platelet Reactivity in Acute Non-disabling Cerebrovascular Events
Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition…
- Trial name
- PRINCE (NCT02506140)
- Testing
- Ticagrelor and Acetylsalicylic acid, Clopidogrel and Acetylsalicylic acid
- Where
- 25 sites in China
- Volunteers
- 675 people
- Sponsor
- Beijing Tiantan Hospital
Unruptured Intracranial Aneurysm, Flow Diverter
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to…
- Conditions
- Unruptured Intracranial Aneurysm, Flow Diverter, Stent-assisted Coiling, Thromboembolic Events
- Trial name
- TEAR (NCT06238115)
- Testing
- Tirofiban, aspirin, clopidogrel
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Beijing Tiantan Hospital
Antiplatelet
Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04237935
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg
- Where
- United States
- Volunteers
- 27,960 people
- Sponsor
- Brigham and Women's Hospital
Healthy
Bioequivalence Study of Clopidogrel Tablets 75 mg Under Fed Conditions
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Laboratories Ltd, clopidogrel and Bristol-Myers Squibb Company, USA Plavix®, clopidogrel 75 mg tablet under fed condition.
- Trial name
- NCT01512485
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Coronary Artery Disease
The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance
Continuing high dose clopidogrel treatment after elective PCI decreased adverse cardiac events in patients with clopidogrel resistance
- Trial name
- EFFICIENT (NCT01032668)
- Testing
- Clopidogrel
- Where
- Turkey (Türkiye)
- Volunteers
- 192 people
- Sponsor
- Bursa Postgraduate Hospital
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Coronary Heart Disease
Treatment of Coronary Heart Disease With Amiloride
Treatment of coronary artery disease is a major health care problem across the entire word, and the United States. Unfortunately, despite a number of medical advances, diagnostic procedure, or epidemiological studies, the…
- Trial name
- NCT01231165
- Testing
- Amiloride, Nitrates, clopidogrel, aspirin, statins
- Where
- Venezuela
- Volunteers
- 70 people
- Sponsor
- University of Carabobo
Peripheral Vascular Diseases
Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel
The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.
- Trial name
- NCT00163267
- Testing
- clopidogrel
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Chronic Coronary Syndrome, Coronary Artery Bypass Graft CABG
Antiplatelet Strategy for CCS Patients Undergoing CABG
To evaluate the long-term outcomes of different antiplatelet strategies, including DAPT, aspirin monotherapy, and clopidogrel monotherapy, in CCS patients undergoing CABG.
- Trial name
- CABG_DAPT_SAPT (NCT06881901)
- Volunteers
- 29,898 people
- Sponsor
- Samsung Medical Center
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation, Cardiovascular Disease
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
The purpose of this study was to determine if Irbesartan compared to Placebo would reduce the risk of vascular events such as heart attack, stroke, non-cerebral thromboembolic event and death in patients with Atrial Fibrillation…
- Trial name
- ACTIVE I (NCT00249795)
- Testing
- Irbesartan
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 9,016 people
- Sponsor
- Sanofi
Left Atrial Appendage Occlusion
Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
Objective: To demonstrate superiority of a strategy of anticoagulation with apixaban 5mg/2.5mg bid as compared with the current standard of care (dual antiplatelet therapy) after occlusion of the left atrial appendage (LAAC) in…
- Trial name
- ADALA (NCT05632445)
- Testing
- Apixaban vs. DAPT
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- DR. XAVIER FREIXA
Stroke, Transient Ischemic Attack
Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II
The primary objective of this trial is to assess the effects of ticagrelor plus aspirin versus clopidogrel plus aspirin on reducing the 3-month risk of any stroke (both ischemic and hemorrhagic, primary outcome) when initiated…
- Trial name
- CHANCE-2 (NCT04078737)
- Testing
- Ticagrelor and Aspirin, Clopidogrel and Aspirin
- Where
- 214 sites in China
- Volunteers
- 6,412 people
- Sponsor
- Beijing Tiantan Hospital
Peptic Ulcer
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
Proton Pump Inhibitors (PPI) can prevent the recurrence of peptic ulcer in clopidogrel users.
- Trial name
- NCT01138969
- Testing
- esomeprazole
- Where
- Taiwan
- Volunteers
- 165 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Ischemia
ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"
To compare the Kinetics of inhibition of platelet aggregation (aggregometry) and platelet activation (flow cytometry) with different loading doses of clopidogrel To evaluate the effect on various parameters of inflammation and…
- Trial name
- NCT00360386
- Testing
- Clopidogrel
- Volunteers
- 110 people
- Sponsor
- Sanofi
Coronary Artery Disease
Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
Because there is limited data about long-term efficacy and safety about short-term use of cilostazol adding to dual antiplatelet therapy in patients with long or multivessel coronary artery disease after 2nd generation DES…
- Trial name
- ABCD (NCT01192724)
- Testing
- Cilostazol, Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 630 people
- Sponsor
- Yonsei University